MJ 451

potassium channel opener; structure in first source

Also Known As:

6-cyano-3,4-dihydro-2,2-dimethyl-2H-3-hydroxy-4-(2-oxo-1-(hydroxymethyl)-1-pyrrolidinyl)-1-benzopyran; MJ 355; MJ-355; MJ-451

Networked: 1 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrans: 130
    - Benzopyrans: 195
      - MJ 451: 1
  - Pyrrolidines: 115
    - Pyrrolidinones: 162
      - MJ 451: 1
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzopyrans: 195
      - MJ 451: 1

Related Diseases

1.	Myocardial Infarction 10/01/1999 - "It is suggested that MJ-355 should be useful in the treatment of hypertension and/or acute myocardial infarction."
2.	Hypertension (High Blood Pressure) 10/01/1999 - "It is suggested that MJ-355 should be useful in the treatment of hypertension and/or acute myocardial infarction."
3.	Myocardial Ischemia (Ischemic Heart Diseases) 10/01/1999 - "In myocardial ischemia, pretreatment of MJ-355 (0.02 mg/kg) significantly reduced the total number of ventricular premature contractions and ventricular tachycardia, total duration of ventricular fibrillation and the mortality. " 10/01/1999 - "The effects of a newly synthesized ATP-sensitive potassium channel opener, MJ-355, on blood pressure and myocardial ischemia-reperfusion injury in rats." 10/01/1999 - "This study was designed to evaluate the effect of MJ-355 (6-cyano-3,4-trans-3,4-dihydro-2,2-dimethyl-2H-3-hydroxy-4-[2-oxo-5S-(1- ethoxyethoxymethyl)-1-pyrrolidinyl]-1-benzopyran), a newly synthesized K(ATP) channel opener, on hemodynamics in spontaneously hypertensive rats and on myocardial ischemia-reperfusion injury in a rat model of 45 min left coronary artery occlusion followed by 1-h reperfusion. "
4.	Reperfusion Injury 10/01/1999 - "The effects of a newly synthesized ATP-sensitive potassium channel opener, MJ-355, on blood pressure and myocardial ischemia-reperfusion injury in rats." 10/01/1999 - "This study was designed to evaluate the effect of MJ-355 (6-cyano-3,4-trans-3,4-dihydro-2,2-dimethyl-2H-3-hydroxy-4-[2-oxo-5S-(1- ethoxyethoxymethyl)-1-pyrrolidinyl]-1-benzopyran), a newly synthesized K(ATP) channel opener, on hemodynamics in spontaneously hypertensive rats and on myocardial ischemia-reperfusion injury in a rat model of 45 min left coronary artery occlusion followed by 1-h reperfusion. "
5.	Ventricular Tachycardia 10/01/1999 - "In myocardial ischemia, pretreatment of MJ-355 (0.02 mg/kg) significantly reduced the total number of ventricular premature contractions and ventricular tachycardia, total duration of ventricular fibrillation and the mortality. "

Related Drugs and Biologics

1.	Benzopyrans
2.	Adenosine Triphosphate (ATP)
3.	KATP Channels